Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells
and either kill them or deliver tumor-killing substances to them without harming normal
cells. It is not yet known if combination chemotherapy is more effective with or without
rituximab for non-Hodgkin's lymphoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy
with or without rituximab in treating older patients who have non-Hodgkin's lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
Eastern Cooperative Oncology Group
Collaborators:
Cancer and Leukemia Group B National Cancer Institute (NCI) Southwest Oncology Group